학술논문

Incorporating progesterone receptor expression into the PREDICT breast prognostic model
Document Type
article
Author
Grootes, IsabelleKeeman, RenskeBlows, Fiona MMilne, Roger LGiles, Graham GSwerdlow, Anthony JFasching, Peter AAbubakar, MustaphaAndrulis, Irene LAnton-Culver, HodaBeckmann, Matthias WBlomqvist, CarlBojesen, Stig EBolla, Manjeet KBonanni, BernardoBriceno, IgnacioBurwinkel, BarbaraCamp, Nicola JCastelao, Jose EChoi, Ji-YeobClarke, Christine LCouch, Fergus JCox, AngelaCross, Simon SCzene, KamilaDevilee, PeterDörk, ThiloDunning, Alison MDwek, MiriamEaston, Douglas FEccles, Diana MEriksson, MikaelErnst, KristinaEvans, D GarethFigueroa, Jonine DFink, VisnjaFloris, GiuseppeFox, StephenGabrielson, MarikeGago-Dominguez, ManuelaGarcía-Sáenz, José AGonzález-Neira, AnnaHaeberle, LotharHaiman, Christopher AHall, PerHamann, UteHarkness, Elaine FHartman, MikaelHein, AlexanderHooning, Maartje JHou, Ming-FengHowell, Sacha JInvestigators, ABCTBInvestigators, kConFabIto, HidemiJakubowska, AnnaJanni, WolfgangJohn, Esther MJung, AudreyKang, DaeheeKristensen, Vessela NKwong, AvaLambrechts, DietherLi, JingmeiLubiński, JanManoochehri, MehdiMargolin, SaraMatsuo, KeitaroTaib, Nur Aishah MohdMulligan, Anna MarieNevanlinna, HeliNewman, William GOffit, KennethOsorio, AnaPark, Sue KPark-Simon, Tjoung-WonPatel, Alpa VPresneau, NadegePylkäs, KatriRack, BrigitteRadice, PaoloRennert, GadRomero, AtochaSaloustros, EmmanouilSawyer, Elinor JSchneeweiss, AndreasSchochter, FabienneSchoemaker, Minouk JShen, Chen-YangShibli, RanaSinn, PeterTapper, William JTawfiq, EssaTeo, Soo HwangTeras, Lauren RTorres, DianaVachon, Celine Mvan Deurzen, Carolien HMWendt, CamillaWilliams, Justin A
Source
Subject
Cancer
Breast Cancer
Breast Neoplasms
Female
Humans
Progesterone
Prognosis
Receptor
ErbB-2
Receptors
Progesterone
PREDICT Breast
breast cancer
Progesterone receptor
ABCTB Investigators
kConFab Investigators
Receptor
erbB-2
Oncology and Carcinogenesis
Public Health and Health Services
Oncology & Carcinogenesis
Language
Abstract
BackgroundPredict Breast (www.predict.nhs.uk) is an online prognostication and treatment benefit tool for early invasive breast cancer. The aim of this study was to incorporate the prognostic effect of progesterone receptor (PR) status into a new version of PREDICT and to compare its performance to the current version (2.2).MethodThe prognostic effect of PR status was based on the analysis of data from 45,088 European patients with breast cancer from 49 studies in the Breast Cancer Association Consortium. Cox proportional hazard models were used to estimate the hazard ratio for PR status. Data from a New Zealand study of 11,365 patients with early invasive breast cancer were used for external validation. Model calibration and discrimination were used to test the model performance.ResultsHaving a PR-positive tumour was associated with a 23% and 28% lower risk of dying from breast cancer for women with oestrogen receptor (ER)-negative and ER-positive breast cancer, respectively. The area under the ROC curve increased with the addition of PR status from 0.807 to 0.809 for patients with ER-negative tumours (p = 0.023) and from 0.898 to 0.902 for patients with ER-positive tumours (p = 2.3 × 10-6) in the New Zealand cohort. Model calibration was modest with 940 observed deaths compared to 1151 predicted.ConclusionThe inclusion of the prognostic effect of PR status to PREDICT Breast has led to an improvement of model performance and more accurate absolute treatment benefit predictions for individual patients. Further studies should determine whether the baseline hazard function requires recalibration.